It has been previously shown that although a median survival after recurrence is longest for ER+ luminal A type breast cancers, the survival is shorter in luminal A and triple negative vs. HER2 positive breast cancers when calculated for date of diagnosis of brain metastases [30,43]. The gene discussed is ERBB2; the disease is breast carcinoma.